Clinical trial · Other
A Study of Orforglipron in Participants With Obesity or Overweight
Lilly-orforglipron-Ph3
Trial identity
- Registry
- Other
- Registry ID
- Lilly-orforglipron-Ph3
- Phase
- Phase 3
- Design
- Interventional
- Allocation
- Randomized
- Masking
- Double-blind
- Overall status
- Recruiting
- Result status
- none
Sponsors & collaborators
- Sponsor
- Eli Lilly
- Collaborators
- —
Intervention assets
Arms
| Arm | Intervention | Enrollment |
|---|---|---|
| Orforglipron | orforglipron oral once daily | — |
| Placebo | placebo oral once daily | — |
Population & enrollment
- Population summary
- Adults with obesity or overweight with comorbidities.
- Eligibility summary
- BMI ≥30 or ≥27 with comorbidity.
- Planned enrollment
- 3000
- Actual enrollment
- 3000
Endpoints
- Primary endpoint
Percent change in body weight from baseline
- Secondary endpoints
Weight loss thresholds
Cardiometabolic parameters
Dates
- Start date
- May 15, 2023
- Primary completion
- Mar 1, 2026
- Completion date
- Sep 1, 2026
- Last synced
- Aug 15, 2024
Locations
- Multiple countries
Plain-language interpretation
A Study of Orforglipron in Participants With Obesity or Overweight is a Phase 3 Interventional sponsored by Eli Lilly. It is evaluating Orforglipron in Adults with obesity or overweight with comorbidities.. The primary endpoint is Percent change in body weight from baseline.
Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against Other.